| Literature DB >> 24830389 |
Bruno de Queiroz Claudio1, Marcelle Azevedo Nossar Costa1, Filipe Penna1, Mariana Teixeira Konder1, Bruno Miguel Jorge Celoria1, Luciana Lopes de Souza1, Roberto Pozzan2, Roberta Siuffo Schneider2, Felipe Neves Albuquerque2, Denilson Campos Albuquerque1.
Abstract
BACKGROUND: Drug-induced increase in QT dispersion has been associated with potentially fatal ventricular arrhythmias. Little is known about the use of psychotropic substances, alone or in combination with other drugs on QT dispersion.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24830389 PMCID: PMC4051449 DOI: 10.5935/abc.20140055
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Distribution of groups according to the reasons for hospital admission
|
|
|
|
|
|
|---|---|---|---|---|
| Orthopedic surgical admissions | 96 | 51 (60) | 45 (59.21) | p = 0.19 |
| Admissions for general and urological surgery | 32 | 20 (23.53) | 13 (17.11) | p = 0.065 |
| Pulmonary sepsis | 21 | 8 (9.41) | 12 (15.79) | p = 0.085 |
| Urinary sepsis | 12 | 6 (7.06) | 6 (7.89) | p = 0.32 |
| Total | 161 | 85 (100) | 76 (100) |
Psychotropics used by the sample population
|
|
|
|
|
|---|---|---|---|
| Haloperidol | 1 | Phenobarbital | 1 |
| Chlorpromazine | 1 | Phenytoin | 2 |
| Levomepromazine | 3 | Lamotrigine | 2 |
| Risperidone | 3 | Carbamazepine | 4 |
| Clozapine | 1 | Oxcarbazepine | 2 |
| Quetiapine | 23 | Gabapentin | 6 |
| Olanzapine | 2 | Valproic acid | 4 |
| Ziprasidone | 0 | Topiramate | 2 |
| Aripiprazole | 0 | Venlafaxine | 4 |
| Promethazine | 3 | Memantine | 7 |
| Amitriptyline | 3 | Mirtazapine | 4 |
| Imipramine | 1 | Duloxetine | 3 |
| Clomipramine | 2 | Fluoxetine | 3 |
| Doxepin | 1 | Paroxetine | 1 |
| Desipramine | 0 | Sertraline | 4 |
| Nortriptyline | 1 | Citalopram | 6 |
| Trazodone | 1 | Citalopram | 3 |
| Bupropion | 2 | Donepezil | 2 |
| Maprotiline | 1 | Rivastigmine | 4 |
| Nefazodone | 0 | Galantamine | 1 |
Antiarrhythmic drugs used by the sample population
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
| ---- |
|
|
|
|
| ||
| Psychotropics + Antiarrhythmics | 0 | 9 | 6 | 1 | 4 | 0 | 20 |
| Antiarrhythmics | 0 | 7 | 4 | 1 | 2 | 1 | 15 |
Demographic, clinical and laboratory data
|
|
|
|
|
|
|---|---|---|---|---|
| Age (years), mean ± standard deviation | 67.68 ± 12.68 | 74.43 ± 11.37 | t = 3.540 | 0.001 |
| Male gender, % | 50.60 | 34.20 | X2 = 4.395 | 0.04 |
| Female gender, % | 49.40 | 65.80 | ||
| SAH, % | 40 | 39.50 | X2 = 0.005 | 1 |
| DM, % | 25.90 | 23.70 | X2 = 0.104 | 0.885 |
| CAD, % | 21.20 | 13.20 | X2 = 1.796 | 0.214 |
| Potassium, mean ± standard deviation (mEq/L) | 4.29 ± 0.55 | 4.31 ± 0.69 | F = 0.493 | 0.852 |
| Magnesium, mean ± standard deviation (mg/dL) | 1.88 ± 0.21 | 1.95 ± 0.34 | F = 6.444 | 0.109 |
| Glycemia, mean ± standard deviation (mg/dL) | 115 ± 40 | 123 ± 46 | F = 1.194 | 0.191 |
Heteroscedastic sample. SAH: systemic arterial hypertension; DM: diabetes mellitus; CAD: coronary artery disease; F: Levene F ratio.
Electrocardiographic data and behavior of QT interval dispersion
|
|
|
|
|
|---|---|---|---|
|
| |||
| QT interval dispersion, mean ± standard deviation (ms) | 57.08 ± 23.4 | 69.25 ± 25.5 | 0.002 |
| Corrected QT interval, mean ± standard deviation (ms) | 427.71 ± 28.42 | 439.79 ± 31.14 | 0.011 |
| Heart rate, mean ± standard deviation (bpm) | 79 ± 15 | 77 ± 18 | 0.379 |
Chart 1Correlation between number of psychotropic agents and QT interval dispersion. r = 0.341, p value < 0.001.
Pearson's linear correlation between the studied variables
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Pearson | 0.341 | 0.177 | -0.103 | 0.057 | -0.054 | 0.095 |
| p value | < 0.001 | 0.024 | 0.195 | 0.471 | 0.495 | 0.232 |
Impact of concurrent use of psychotropic agents and antiarrhythmic drugs vs. isolated use of antiarrhythmic drugs
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Psychotropic + antiarrhythmic drugs | 20 | 445.1 ± 23.77 | 0.023 | 63.55 ± 21.11 | 0.715 |
| Antiarrhythmics | 15 | 421.7 ± 24.01 | 66.60 ± 23.22 |